Management of Residual Neuromuscular Blockade Recovery: Age-Old Problem with a New Solution.
Publication/Presentation Date
1-1-2017
Abstract
Neostigmine has been traditionally used as the agent of choice to reverse Neuromuscular Blockade (NMB) after muscle paralysis during general anesthesia. However, the use of neostigmine has not been without untoward events. Sugammadex is a novel drug that selectively binds to aminosteroid nondepolarizing muscle relaxants and reverses even a deep level of NMB. Controversy exists regarding the optimal dose of sugammadex that is effective in reversing the NMB after the incomplete reversal with neostigmine and glycopyrrolate. We discuss a case where sugammadex reduced the time of the recovery from NMB in a patient who had incomplete antagonisms following adequate treatment with neostigmine, aiding timely extubation without persistent residual NMB, and hence prevented the requirement of postoperative ventilation and the improvement in patient care. More randomized control studies are needed in order to conclude the appropriate dose of sugammadex in cases of incomplete reversal.
Volume
2017
First Page
8197035
Last Page
8197035
ISSN
2090-6382
Published In/Presented At
Green, M. S., Venkatesh, A. G., & Venkataramani, R. (2017). Management of Residual Neuromuscular Blockade Recovery: Age-Old Problem with a New Solution. Case reports in anesthesiology, 2017, 8197035. https://doi.org/10.1155/2017/8197035
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
28392946
Department(s)
Administration and Leadership
Document Type
Article